OROle Roikjaer

Ole Roikjaer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ole Roikjaer has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lymph node yield and tumour subsite are associated with survival in stage I–III colon cancer: results from a national cohort study

    by On behalf of the Danish Colorectal Cancer Group, Jakob Lykke, Jacob Rosenberg, Per Jess, Ole Roikjaer

    It has been suggested that apart from tumour and nodal status, a range of patient-related and histopathological factors including lymph node yield and tumour location seems to have prognostic implications in stage I–III colon cancer. We analysed the prognostic implication of lymph node yield and tumour subsite in stage I–III colon cancer. Data on patients with stage I to III adenocarcinoma of the colon and treated by curative resection in the period from 2003 to 2011 were extracted from the Danish Colorectal Cancer Group database, merged with information from the Danish National Patient Register and analysed. A total of 13,766 patients were included in the analysis. The 5-year overall survival ranged from 59.3% (95% CI 55.7–62.9%) (lymph node yield 0–5) to 74.0% (95% CI 71.8–76.2%) (lymph node yield ≥ 18) for patients with stage I–II disease (p < 0.0001) and from 36.4% (95% CI 29.8–43.0%) (lymph node yield 0–5) to 59.4% (95% CI 56.6–62.2%) (lymph node yield ≥ 18) for patients with stage III disease (p < 0.0001). The 5-year overall survival for tumour side left/right was 59.3% (95% CI 57.9–60.7%)/64.8% (CI 63.4–66.2%) (p < 0.0001). In the seven colonic tumour subsites, the 5-year overall survival ranged from 56.6% (95% CI 51.8–61.4%) at splenic flexure to 65.8% (95% CI 64.5–67.2%) in the sigmoid colon (p < 0.0001). In a cox regression analysis, lymph node yield and tumour side right/left were found to be prognostic factors. Tumours at the hepatic and splenic flexures had an adverse prognostic outcome. For stage I–III colon cancer, a lymph node yield beyond the recommended 12 lymph nodes was associated with improved survival. Both subsite in the right colon, as well as subsite in the left colon, turned out with adverse prognostic outcome questioning a simple classification into right-sided and left-sided colon cancer.


  • Three years of colorectal cancer screening in Denmark

    by Sisse Helle Njor, Lennart Friis-Hansen, Berit Andersen, Bo Søndergaard, Dorte Linnemann, Jens Christian Riis Jørgensen, Ole Roikjær, Morten Rasmussen


  • A model predicting operative mortality in the UK has only limited value in Denmark

    by Thea Helene Degett, Ole Roikjær, Lene Hjerrild Iversen, Ismail Gögenur

    Postoperative mortality from colorectal cancer varies between surgical departments. Several models have been developed to predict the operative risk. This study aims to investigate whether the original and the revised Association of Coloproctology of Great Britain and Ireland (ACPGBI) model can predict 30-day mortality after colorectal cancer surgery in Denmark.


  • A high lymph node yield in colon cancer is associated with age, tumour stage, tumour sub-site and priority of surgery. Results from a prospective national cohort study

    by On behalf of the Danish Colorectal Cancer Group, Jakob Lykke, Per Jess, Ole Roikjær

    Aim To determine the relation between patient-related and histopathological factors, as well as the influence of national programs for diagnosing and treatment of colon cancer and a lymph node yield (LNY) ≥ 12. Method An analysis was carried out of the LNY in a nationwide Danish cohort treated by curative resection of stage I–III colon cancer in the period 2003–2011. The association between a LNY ≥ 12 and age, sex, body mass index, open vs. laparoscopic surgery, acute vs. elective surgery, pT stage, tumour sub-site and year of diagnosis was analysed. Results A total of 13,766 patients were eligible for the analysis. In total, 71.4 % of the patients had a LNY ≥ 12. In multivariate analysis, age, pT stage, tumour sub-site and priority of surgery were independently associated with the probability of a LNY ≥ 12. Odds ratios (ORs) were as follows: age 75 0.517 (CI 0.439–0.609); T1 1, T2 2.750 (CI 2.168–3.487), T3 6.016 (CI 4.879–7.418), T4 6.317 (CI 4.950–8.063); right colon 1, left colon 0.568 (0.511–0.633); elective surgery 1, acute surgery 0.748 (CI 0.625–0.894). Moreover, year of diagnosis was associated with the probability of a LNY ≥ 12: OR 1.480 (CI 1.445–1.516) for each increasing year in the study period. Conclusion A LNY ≥ 12 is significantly associated with age, pT stage, tumour sub-site and priority of surgery. A significant increase in the LNY over the period of the study was observed, probably reflecting the effect of national programmes initiated by the Danish Colorectal Cancer Group.


  • Increased Lymph Node Yield Is Associated With Improved Survival in Rectal Cancer Irrespective of Neoadjuvant Treatment

    by Jakob Lykke, Per Jess, Ole Roikjaer

    It has been proposed that the lymph node yield achieved during rectal cancer resection is associated with survival. It is debated whether a high lymph node yield improves survival, per se, or whether it does so by diminishing the International Union Against Cancer stage drifting effect. The purpose of this study was to evaluate the prognostic implications of the lymph node yield in curative resected rectal cancer. This study was based on data from a prospectively maintained colorectal cancer database. This was a national cohort study. All 6793 patients in Denmark who were diagnosed with International Union Against Cancer stage I to III adenocarcinoma of the rectum and so treated in the period from 2003 to 2011 were included in the analysis. The primary outcome measure was overall survival. The observed percentages of patients with International Union Against Cancer stage III disease with a lymph node yield less than 12 or 12 or more were 28.1 % and 40.7% (p < 0.0001) in the non-neoadjuvant treatment group and 26.9% and 38.3% (p < 0.0001) in the neoadjuvant treatment group. The 5-year overall survival rates for patients with a lymph node yield <12 or 12 or more were 73.1% and 80.6% in International Union Against Cancer stages I to II (p < 0.0001) and 57.4% and 53.3% in stage III (p < 0.142) in the neoadjuvant treatment group and 70.4% and 79.2% in stages I to II (p < 0.0001) and 46.6% and 59.1% in International Union Against Cancer stage III (p < 0.0001) in the non-neoadjuvant treatment group. In multivariate analysis, the lymph node yield turned out to be an independent prognostic factor, irrespective of neoadjuvant treatment. It is not possible in an observational study to tell whether the findings are associations rather than causal relationships. Increased lymph node yield was associated with better overall survival in rectal cancer, irrespective of neoadjuvant treatment. Stage migration was observed.


  • A minimum yield of twelve lymph nodes in rectal cancer remains valid in the era of neo-adjuvant treatment

    by On behalf of the Danish Colorectal Cancer Group, Jakob Lykke, Per Jess, Ole Roikjaer

    The purpose of the study was to examine if a minimum of 12 lymph nodes (LNs) is still valid in rectal cancer after neo-adjuvant treatment. An analysis was carried out in a nationwide Danish cohort of 6793 patients, treated by curative resection of stage I–III rectal cancer during the period 2003–2011. The cohort was divided into two groups according to whether neo-adjuvant treatment had been given. The groups were analysed separately and were further analysed according to four lymph node yield (LNY) groups 0–5, 6–11, 12–17 and ≥18. Two thousand one hundred twenty-three patients (31.0 %) received neo-adjuvant treatment. A median LNY of 10 and 15 (p < 0.0001) and rates of node-positive (N-positive) disease of 31.6 and 36.7 % (p < 0.001) were observed with and without (+/−) neo-adjuvant treatment, respectively. The rate of N-positive disease according to tumour stage ranged from 4.8 %/11.4 % (ypT0/pT1) to 42.1 %/64.1 % (ypT4/pT4). The rate of N-positive disease according to LNY ranged from 19.5 %/16.8 % (0–5 LNs) to 42.6 %/37.9 % (≥18 LNs) (−/+neo-adjuvant treatment). In a logistic regression analysis, a significant association was found between N-positive disease and pT/ypT stage as well as between N-positive disease and LNY. A significantly smaller ratio of N-positive disease was observed in the group of patients who had received neo-adjuvant treatment. The ratio of N-positive disease increased significantly with more advanced tumour stage and increasing LNY irrespective of neo-adjuvant treatment. A minimum of 12 LNs is needed to ensure N-negative disease, irrespective of neo-adjuvant treatment.


  • Tumour stage and preoperative chemoradiotherapy influence the lymph node yield inStagesI–IIIrectal cancer: results from a prospective nationwide cohort study

    by J. Lykke, O. Roikjær, P. Jess, the Danish Colorectal Cancer Group

    Aim: The study aimed to determine whether the lymph node yield (LNY) in rectal cancer is influenced by patient‐related and histopathological factors and the use of preoperative chemoradiotherapy (CRT).Method: An analysis was carried out of theLNYin a nationwideDanish cohort of 7950 patients, treated by curative resection ofStageI–IIIrectal cancer during the period 2001–2011. The impact of year of diagnosis, age, gender, pathological stage of the tumour (pT‐stage) and preoperativeCRTonLNYwas analysed.Results: Twenty‐nine per cent of the patients received preoperativeCRT. The medianLNYwas 13 [interquartile range (IQR): 8–19]. A total of 43.4% of the patients had anLNYof < 12. The medianLNYincreased from 8 (IQR: 5–12) to 20 (IQR: 13–28)LNs over the years of the study period (P < 0.0001). Gender and body mass index (BMI) had no impact on the medianLNY. Age had a minor impact, with a range of 12 (IQR: 8–18) to 13 (IQR: 9–20) (P < 0.0001). TheLNYranged from 9 (IQR: 6–14) to 16 (IQR: 10–26), according to pT‐stage (pT0–pT4) (P < 0.0001). MedianLNY, according to preoperativeCRTor no preoperativeCRT, was 10 (IQR: 6–16) and 14 (IQR: 8–18), respectively (P < 0.0001). The percentages of patients with anLNYof < 12, according to preoperativeCRTor no preoperativeCRT, were 58.7% and 37.1%, respectively (P < 0.0001).Conclusion: An increase in theLNYover the period of the study was observed, probably reflecting improved quality of surgery and histopathology. A minor significant reduction ofLNYwas found with increasing age of the patient.LNYwas significantly related to pT‐stage and to the use of preoperative chemoradiotherapy. For these reasons the minimum harvest of 12LNs as a surrogate marker for the oncological quality of surgery should be questioned.


    • 1 July 2013
      • Vol. 60  (7) , A4664

    The majority of surgical departments adhere to national Danish guidelines for surveillance after colorectal cancer surgery.

    by Jakob Lykke, Ole Roikjær, Per Jess

    In 2003 the use of post-operative surveillance (POS) after surgery for colorectal cancer (CRC) in Denmark was studied. Diversity in the choice and frequency of surveillance modalities was found. Subsequently, the Danish Colorectal Cancer Group (DCCG) has published guidelines for POS. In the same period, the number of departments performing CRC surgery has been reduced by 50% nationally. The aim of the present study was to describe the POS after CRC in Denmark following a reduction in the number of departments performing operations for CRC and the DCCG's publication of national recommendations for POS programmes. Questionnaires were sent to all 19 departments that performed operations for CRC. Questions concerned the diagnostic modalities used for detecting recurrences and metachrone cancers. All departments returned their questionnaires. All departments had a formal POS programme. The recommendations given by the DCCG were met by 17 departments (89%) with regard to liver metastases, by 16 departments (84%) with regard to lung metastases and by 16 departments (84%) with regard to metachrone cancers. As opposed to what was observed in 2003, all departments offered a POS programme after CRC surgery in 2012. Almost all departments met the DCCG recommendations, probably owing to the centralization of CRC surgery and the DCCG's introduction of national guidelines. Hopefully, this will contribute to a better survival for CRC patients in the future, although more research is needed to establish optimal post-operative surveillance. not relevant. not relevant.